Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Биомаркеры сердечно-сосудистых заболеваний
2006-05-15
SCID: 54.1/g3ya3xg3
Discuss with AI
biomarkerscardiovascular disease (CVD)prognosticationrisk stratificationsubclinical disease
Figures from the paper
Abstract (AI)
C ardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the United States. 1 Primary prevention and secondary prevention of CVD are public health priorities. 2 Substantial data indicate that CVD is a life course disease that begins with the evolution of risk factors that in turn contribute to the development of subclinical atherosclerosis.3,4 Subclinical disease culminates in overt CVD.5,6 The onset of CVD itself portends an adverse prognosis with greater risk of recurrent events, morbidity, and mortality.7,8 It is also increasingly clear that although clinical assessment is the keystone of patient management, such evaluation has its limitations.9 -12 Clinicians have used additional tools to aid clinical assessment and to enhance their ability to identify the "vulnerable" patient at risk for CVD, as suggested by a recent National Institutes of Health (NIH) panel.13,14 Biomarkers are one such tool to better identify high-risk individuals, to diagnose disease conditions promptly and accurately, and to effectively prognosticate and treat patients with disease.This review provides an overview of the molecular basis of biomarker discovery and selection and the practical considerations that are a prerequisite to their clinical use.
Key Findings
1
Biomarkers can help identify high-risk individuals, enable prompt and accurate diagnosis, and improve prognostication and treatment.
2
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the United States.
3
Clinical assessment alone has limitations in identifying patients at risk for CVD, motivating use of additional tools.
4
Subclinical CVD progresses to overt disease, which associates with higher risk of recurrent events, morbidity, and mortality.
5
The review outlines the molecular basis for biomarker discovery and practical considerations required for clinical biomarker use.
Research Object
Biomarkers for cardiovascular disease
Research Subject
Their utility for identifying high-risk (vulnerable) individuals, diagnosing subclinical and overt CVD, prognostication, treatment guidance, and the molecular basis and practical considerations for biomarker discovery and clinical implementation
Publication Details
Publication Date
2006-05-15
Journal
Publisher
ISSN
Cited by
1245
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Initial sequencing and analysis of the human genome2001
A haplotype map of the human genome2005
Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease2000
Assessing the Probability That a Positive Report is False: An Approach for Molecular Epidemiology Studies2004
Prognostic Significance of Serial Changes in Left Ventricular Mass in Essential Hypertension1998